NRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on Thursday

NRx Pharmaceuticals (NASDAQ:NRXP) is scheduled to be announcing its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.81) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.06. On average, analysts expect NRx Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $1.26 on Wednesday. The stock has a market cap of $13.55 million, a price-to-earnings ratio of -0.47 and a beta of 1.27. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $7.33. The firm’s 50-day moving average is $1.48 and its 200 day moving average is $2.26.

Analysts Set New Price Targets

Several research analysts have recently issued reports on NRXP shares. HC Wainwright raised their price target on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, August 5th. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Ascendiant Capital Markets lifted their target price on NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, September 12th.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.